UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for its therapy ZILBRYSQ (zilucoplan). The recommendation introduces a new pre-filled pen device designed for self-administration as an add-on to standard therapy for adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
The CHMP’s positive opinion marks a significant step toward expanding patient-friendly treatment options in Europe. If formally approved by the European Commission, the pre-filled pen will complement the existing pre-filled syringe presentation, which is already authorized for subcutaneous self-administration by patients or caregivers.
Zilucoplan is currently the first once-daily, subcutaneous C5 inhibitor for gMG in Europe, and the addition of a pre-filled pen introduces a more convenient and potentially less intimidating delivery option. The device is designed to automatically administer a precise dose through a push-on-skin activation mechanism, eliminating the need for manual injection techniques.
According to Donatello Crocetta, the innovation reflects UCB’s dual focus on advancing both therapeutic science and patient experience. He emphasized that simplifying the administration process can improve confidence in self-management while maintaining the established efficacy and safety profile of the therapy.
The new delivery system is expected to offer greater flexibility for patients managing a chronic condition that often requires long-term treatment. Its portable design allows for easier integration into daily routines, supporting adherence and independence. Additionally, the concealed needle feature may help reduce anxiety for individuals with needle-related concerns, a common barrier to consistent self-injection.
Clinical experts have also highlighted the importance of combining therapeutic effectiveness with real-world usability. Mary Petrulis noted that the simplified administration approach could enhance patient confidence while preserving the established clinical benefits of zilucoplan.
Beyond patient convenience, the pre-filled pen aligns with UCB’s sustainability goals. The company reported that the optimized product and packaging design could reduce carbon dioxide emissions by up to 50% compared to traditional production methods, reflecting a broader commitment to environmentally responsible innovation.
Overall, the CHMP’s recommendation underscores growing momentum in developing patient-centric treatment solutions for rare autoimmune diseases. With regulatory approval pending, the new pre-filled pen could soon provide individuals living with gMG across Europe with a more accessible and user-friendly way to manage their condition.